Nanotechnology is poised to make potentially revolutionary innovations in areas of biomedical science, such as gene therapy and drug therapy. A recently developed nanodelivery strategy involves the use of hydrophilic polymers as carriers of proteins and siRNA. By controlling the reaction conditions during polymer production, various degrees of anionic charge, cationic charge, and cross-linking can be added, thereby changing their capabilities as protein and nucleic acid carriers and promoting effective cell membrane permeation. The efficiency of a specific controlled-release polymeric system is determined in part by its unique physical and chemical properties and biodegradation rate. In this review, we will summarize recent progress in the ability to modify drug release of hydrophilic polymers nanoparticles.

There are several barriers to gene delivery. One of the biggest challenges is the design of appropriate vectors. Currently, nonviral vectors have received significant attention because of low toxicity, potential for tissue specificity, stability during storage, lack of immunogenicity, and relatively low production cost. Despite the high efficiency of viral vectors, they show limited clinical applications because of potentially fatal adverse effects and because of the likelihood of the immune response shutting down the transgene expression system. Nonviral technologies comprise plasmid‐based expression systems harboring a gene that encodes a therapeutic protein along with a synthetic gene delivery system. This review provides a broad perspective on recent improvements in the development of four kinds of nonviral vectors that are based on polymers, peptides, lipids, and DNA and discusses the cytotoxicity associated with gene therapy. Copyright © 2014 John Wiley & Sons, Ltd.

Background Although recent studies have indicated that imbalance in the respiratory microbiome composition is linked to several chronic respiratory diseases, the association between the lung microbiome and lung cancer has not been extensively studied. Conflicting reports of individual studies on respiratory microbiome alterations in lung cancer complicate the matter for specifying how the lung microbiome is linked to lung cancer. Consequently, as the first meta-analysis on this topic, we integrate publicly available 16S rRNA gene sequence data on lung tissue samples of lung cancer patients to identify bacterial taxa which differ consistently between case and control groups. Results The findings of the current study suggest that the relative abundance of several bacterial taxa including Actinobacteria phylum, Corynebacteriaceae and Halomonadaceae families, and Corynebacterium, Lachnoanaerobaculum, and Halomonas genera is significantly decreased (p < 0.05) in lung tumor tissues of lung cancer patients in comparison with tumor-adjacent normal tissues. Conclusions Despite the underlying need for scrutinizing the findings further, the present study lays the groundwork for future research and adds to our limited understanding of the key role of the lung microbiome and its complex interaction with lung cancer. More data on demographic factors and tumor tissue types would help establish a greater degree of accuracy in characterizing the lung microbial community which accords with subtypes and stages of the disease and fully capturing the changes of the lung microbiome in lung cancer.

Fe3O4 superparamagnetic nanoparticles were used in magnesium based Janus micromotors for the first time and the bactericidal activity of the micromotors reached nearly 100%.